**Core Concept**
B cell prolymphocytic leukemia (B-PLL) is a rare, aggressive hematologic malignancy characterized by clonal expansion of prolymphocytes, while B cell chronic lymphocytic leukemia (B-CLL) is a more indolent, slowly progressing disease. The key distinction lies in disease progression, prognosis, and survival outcomes.

**Why the Correct Answer is Right**
B-PLL is an aggressive lymphoproliferative disorder with rapid progression and poor prognosis. Patients typically have a median survival of 1–2 years, significantly shorter than B-CLL patients, who often survive for over 10 years. This difference arises due to the biology of prolymphocytes—more proliferative and less responsive to therapy—leading to faster disease progression and higher risk of transformation. B-CLL, in contrast, is characterized by slow accumulation of mature B cells with a favorable long-term outlook.

**Why Each Wrong Option is Incorrect**
Option A: B-PLL often presents in older adults, similar to B-CLL, and does not consistently present at a younger age.
Option B: B-PLL patients usually have elevated white cell counts, not lower total leucocyte counts.
Option C: Lymphadenopathy is common in both, but more prominent in B-CLL, not B-PLL.

**Clinical Pearl / High-Yield Fact**
B-PLL is a diagnosis of exclusion and mimics CLL clinically, but its aggressive course and poor survival make early recognition critical. Always consider B-PLL in older patients with atypical lymphocytosis and rapid progression.

✓ Correct Answer: D. Having a shorter survival